[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Changi General Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":318},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,42,70,96,126,155,176,204,236,259,290],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100634810","feasibility-safety-and-efficacy-of-a-predominantly-plant-based-diet-in-an-asian-population-with-chronic-kidney-disease-100634810",false,"NCT07544524","Feasibility, Safety and Efficacy of a Predominantly Plant-based Diet in an Asian Population With Chronic Kidney Disease","Inclusion Criteria:\n\n1. Age 21-79 (Only adults who can give consent will be recruited. Older adults aged 80 are not included to reduce the risk of confounding due to age-related frailty, sarcopenia and multimorbidity. Additionally, older adults may have different nutritional needs and energy requirements)\n2. CKD stage 3-4 (baseline eGFR 15-60ml\u002Fmin\u002F1.72m2 for the past 6 months)\n3. Willingness to see a dietitian and follow either a standard CKD diet or a predominantly plant-based CKD diet\n4. On maximum tolerated dose of ACE-inhibitors (Angiotensin converting enzyme inhibitors) or ARB (Aldosterone receptor blocker) as determined by Renal Physician in charge\n5. Able to provide informed consent\n\nExclusion Criteria:\n\n* Transplant patients (who will tend to have more variable trajectories, immunosuppression related challenges etc which may make this study less feasible)\n* Pregnant or lactating patients (who have different nutritional requirements than the standard CKD patients)\n* Patients who were on any special diet for at least 1 month prior to recruitment (inclusive of\n* long-term vegans or vegetarians) - excluded because they already have stable dietary habits\n* Age \\\u003C21 or \\>\u002F= 80 (Avoid growing children who have different nutritional requirements and advanced elderly who are more likely to have malnutrition or sarcopenia due to other pre-existing causes)\n* Those who have seen a dietitian for CKD previously\n* Patients with severe ischemic heart disease, decompensated liver cirrhosis, malabsorptive diseases or malignancy\n* Patients with BMI \\\u003C18.5 or \\>40\n* Patients with glomerulonephritis, genetic kidney disease or polycystic kidney disease\n* Baseline serum potassium 5.0 and above\n* Patients who are unable to modify their diet due to socio-economic issues.\n* Exclude patients with acute kidney injury (AKI) in the past 6 months prior to study (unstable renal disease","ALL","21 Years","79 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"NA","This two-year follow up, single-center, open-label, feasibility study will recruit outpatients from the Renal Medicine Clinic at Changi General Hospital. Eligible patients with Stage 3 or 4 CKD will be assigned preferencebased to either a plant-based diet intervention (intake of at least 50% protein from plant sources) with regular dietitian counselling and follow up, or a control group receiving dietitian counselling for general CKD dietary advice without information on percentage of plant-based foods. Six monthly assessments will include estimated glomerular filtration rate (eGFR), serum potassium, nutritional markers, and other relevant biochemical parameters. Quality of life and dietary adherence will be evaluated through questionnaires and food frequency records. This study will evaluate primarily, the feasibility of a plant-based diet in the Singaporean context. Secondarily it will evaluate its safety in terms of incidence of hyperkalaemia, and benefit in terms of improvement in acidosis.\n\nOther exploratory outcomes will include (1) preliminary efficacy of plant-based diets on CKD progression (measured by eGFR decline); (2) risk of nutritional deficiencies such as vitamin D, B12 and iron; and (3) impact on other biochemical parameters of CKD.",[26,27,28],"Chronic Kidney Disease stage3","Chronic Kidney Disease stage4","Diet Habit","RECRUITING","2026-04-15",{"date":32,"type":33},"2026-04-22","ACTUAL",{"date":35,"type":20},"2026-04-01",{"date":37,"type":20},"2027-09-30",{"name":39,"class":40},"Changi General Hospital","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":15,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":53,"conditions":54,"keywords":61,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":41},"100608713","a-randomized-controlled-trial-comparing-whole-body-vibration-therapy-with-usual-care-and-usual-care-to-improve-muscle-health-in-older-adults-100608713","NCT07205133","A Randomized Controlled Trial Comparing Whole Body Vibration Therapy With Usual Care and Usual Care to Improve Muscle Health in Older Adults","Effectiveness of Whole Body Vibration Therapy and Usual Care Compared to Usual Care in Improving Muscle Mass, Strength and Function in Older Adults","Inclusion Criteria:\n\n* Healthy Volunteer or Patients aged 65 and above,\n* Clinical frailty Scale (CFS) score of 3-4,\n* Independently ambulating without any aid\n* willingness and consent to participate in the study and ability to travel to the study-site for the measurements and interventions, and\n* participants with no regular exercise habits (defined as less than 150mins\u002Fweek of moderate intensity aerobic exercise and less than twice a week of strengthening exercises)for past 3 months.\n\nExclusion Criteria:\n\n* current active enrolment into any Day Rehab or community exercise program,\n* contraindications to WBVT machine usage (see below),\n* diagnosis of dementia,\n* history of Diabetes Mellitus\n* BMI ≤20kg\u002Fm2,\n* recent hospital admissions within the last 3 months,\n* end stage organ failure,\n* chronic diseases which are not well managed, for example, poorly controlled hypertension,\n* New York Heart Association (NYHA) score II and above for patients with history of heart failure and\n* MUST Score ≥1.\n\nContraindications to WBVT:\n\nPRIMARY CONTRAINDICATIONS TO WBVT\n\n* Pregnancy\n* Acute thrombosis (acute vascular occlusion)\n* Artificial joints in stimulated body regions\n* Fresh fractures in stimulated body regions\n* Within 3 months post surgery\u002Fprocedure and\u002For any fresh wounds and scars in the stimulated body regions\n* or if the wound healing is not yet completely finished.\n\nSECONDARY CONTRAINDICATIONS TO WBVT\n\n* Acute inflammation of the musculoskeletal system, activated arthrosis or\n* arthropathy (e.g. acute inflammation and swelling in joints).\n* Acute tendinopathies in stimulated body regions (acute tendonitis)\n* Acute hernias (tissue ruptures)\n* Acute discopathy (acute disc-related back problem)\n* Stone disease of the bile ducts and urinary tract\n* Rheumatoid Arthritis\n* Epilepsy due to secondary risk of injury",true,"65 Years",{"count":19,"type":20},[23],"This study is a randomized controlled trial where participants would be randomly assigned to one of 2 groups. One group would receive Whole body vibration therapy and usual care and the other group only usual care. Measurements of muscle mass, strength and function would be taken before the interventions, and at 2 other points after interventions. Differences in the outcomes between the two groups would be analysed.",[55,56,57,58,59,60],"Aging","Frailty","Sarcopenia","Muscle Strength","Muscle Function","Muscle Mass",[55,56,57,62,58,59,60],"Whole Body Vibration Therapy","2026-04-14",{"date":30,"type":33},{"date":66,"type":33},"2026-01-10",{"date":68,"type":20},"2027-03-31",{"name":39,"class":40},{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":41},"100492216","gut-microbiome-and-metabolome-in-patients-with-gallstone-disease-after-surgical-and-endoscopic-interventions-100492216","NCT05689255","Gut Microbiome and Metabolome in Patients With Gallstone Disease After Surgical and Endoscopic Interventions","A Prospective Cohort Study of Translational Changes in Gut Microbiome and Metabolome in Patients With Gallstone Disease After Surgical and Endoscopic Interventions","Inclusion Criteria:\n\n* Aged 21 years to 80 years\n* Diagnosis of symptomatic gallstone disease without or with concomitant bile duct stones based on prior diagnostic radiological imaging such as transabdominal ultrasound (US), computed tomography (CT), magnetic resonance imaging (MRI) or endoscopic ultrasound (EUS).\n* Will be scheduled for cholecystectomy with or without concomitant ERCP-ES for treatment.\n* Patient is willing to provide informed consent before enrolment in the study.\n\nExclusion Criteria:\n\n* Subjects undergoing ERCP-ES with no intention for future cholecystectomy\n* Use of antibiotics or probiotics within 1 month (exception: use of antibiotics within 48 hours of cholecystectomy or ERCP, as metagenomics will be able to sequence both dead and live bacteria, and marked compositional change is not expected within this time frame)\n* Presence of malignancy diagnosed within the last 1 year\n* Previous gastrectomy, appendicectomy, small bowel or large bowel surgery\n* Inflammatory bowel disease\n* Active gastrointestinal tract infections","80 Years",{"count":79,"type":20},65,"OBSERVATIONAL","The goal of this longitudinal observational cohort study is to examine the changes in the composition and diversity of gut microbiome and systemic metabolome in patients with symptomatic gallbladder stones with or without concomitant common bile duct (CBD) stones who will be undergoing cholecystectomy with or without prior endoscopic sphincterotomy (ERCP-ES) and CBD stones extraction. The main questions it aims to answer are whether there are:\n\n* differences in gut microbiome diversity and composition before and after cholecystectomy\n* differences in systemic metabolome before and after cholecystectomy\n* gut microbiome and systemic metabolome changes after cholecystectomy\n\nParticipants will be asked to provide stool, urine, plasma and saliva samples prior to and 1-6 months after cholecystectomy. For patients with concomitant CBD stones who undergo ERCP-ES before cholecystectomy, bile specimens will be collected from the bile duct during ERCP-ES as well as the gallbladder and\u002For during cholecystectomy.",[83,84],"Gallstone Disease","Bile Duct Diseases",[86,87],"microbiome","metabolome","2026-04-06",{"date":90,"type":33},"2026-04-09",{"date":92,"type":33},"2022-12-23",{"date":94,"type":20},"2026-12-31",{"name":39,"class":40},{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":21,"phases":107,"briefSummary":108,"conditions":109,"keywords":112,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":41},"100597507","concurrent-trials-on-nature-based-therapy-for-inpatients-in-dementia-and-rehabilitation-medicine-wards-100597507","NCT07059390","Concurrent Trials on Nature-Based Therapy for Inpatients in Dementia and Rehabilitation Medicine Wards","Changi General Hospital Complementary Health Therapy","TGIF","Inclusion Criteria:\n\nPatients with dementia:\n\n1. Age 65-100 years old\n2. Have a diagnosis of delirium\u002F dementia or both.\n3. Have diagnosis of dementia with and without behavioural symptoms of dementia (BPSD)\n4. Ability to communicate with the Nature-based Therapist (in languages such as English, Mandarin Chinese, Chinese dialects or Malay)\n5. Manageable behavioural symptoms and able to focus attention for minimum of 30 minutes\n\nRehabilitation Medicine patients:\n\n1. Age 21-100 years old\n2. Acquired brain injury with residual impairments, which can be either in the i) motor, and\u002For ii) cognitive domains, and\u002For iii) suspected or diagnosed mood disorders (including adjustment disorder, depression and anxiety disorders) -patients would then be stratified according to the category(s) of impairments both for consideration of interventions and for outcome measures\u002Fanalysis\n3. Additional Physical\u002FCognitive Criteria required will depend on range of specific therapeutic activities that could be prescribed\u002Fadministered (eg.at least 1 upper limb with Manual Muscle Testing (MMT) of at least 3\u002F5, with ability for active grasp\u002Frelease, ability to sustain attention for the duration of the session, cognitive Functional Independence Measure (FIM) score of at least 25 points etc)\n\nExclusion Criteria:\n\n1. In isolation due to contact, droplet or airborne precautions\n2. Unable to provide consent and lack of surrogate decision maker to provide consent\n3. Poorly managed psychiatric or behaviour symptoms with threats to others surrounding them.\n4. Age \\\u003C 21 years\n5. Patients who are haemodynamically unstable.\n6. Patients on strict bed rest","100 Years",{"count":106,"type":20},1600,[23],"Nature-based Therapy, such as forest bathing and horticultural therapy, has been shown to have physical, psychological and emotional health benefits. We posit that personalised and guided Nature-based Therapy, which leverages the benefits of therapeutic gardens in an urban hospital setting, improves the overall wellbeing of elderly inpatients with dementia (aged \\>65 years old) and their caregivers, as well as patients undergoing inpatient rehabilitation. To determine the effectiveness of Nature-based Therapy for these two inpatient populations, we designed a pilot study, TGIF, to be conducted at the dementia and rehabilitation medicine wards at Changi General Hospital in Singapore.",[110,111],"Dementia","Acquired Brain Injury Including Stroke",[110,113,114,115,116],"Stroke","Traumatic Brain Injury","Delirium","Nature-Based Therapy","NOT_YET_RECRUITING","2026-03-19",{"date":120,"type":33},"2026-03-23",{"date":122,"type":20},"2027-05",{"date":124,"type":20},"2028-08",{"name":39,"class":40},{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":21,"phases":134,"briefSummary":135,"conditions":136,"keywords":139,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":154},"100615833","trial-of-aldosterone-hybrid-steroid-for-guiding-curable-treatment-of-primary-aldosteronism-target-pa-100615833","NCT07297745","Trial of Aldosterone-hybrid SteRoid for Guiding curablE Treatment of Primary Aldosteronism (TARGET-PA)","Inclusion Criteria:\n\n* Confirmed diagnosis of primary aldosteronism according to the Endocrine Society guideline 2025.\n* Willing to undergo subtype testing with adrenal vein sampling and\u002For molecular imaging (Positron Emission Tomography\u002FComputed Tomography, PET\u002FCT).\n* Keen for surgical treatment if shown to have unilateral primary aldosteronism.\n\nExclusion Criteria:\n\n* Inability to provide written informed consent.",{"count":133,"type":20},120,[23],"The goal of this project is to improve the diagnostic pathway for patients with primary aldosteronism, by validating non-invasive biomarkers coupled with routine computed tomography imaging. The aim is to reduce reliance on invasive procedures, shorten diagnostic timelines, and enhance accessibility to definitive diagnosis and treatment globally.",[137,138],"Hyperaldosteronism; Primary","Primary Aldosteronism Due to Aldosterone Producing Adenoma",[140,141,142,143,144,145],"Hybrid hormone","Subtyping","adrenalectomy","adrenal vein sampling","biomarkers","steroid profiling","2026-01-07",{"date":148,"type":33},"2026-01-09",{"date":150,"type":20},"2026-01-15",{"date":152,"type":20},"2029-12-31",{"name":39,"class":40},4,{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":49,"sex":15,"minAge":16,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":21,"phases":164,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":41},"100590691","programmable-smart-watch-for-remote-pre-habilitationrehabilitation-monitoring-100590691","NCT06970717","Programmable Smart Watch for Remote Pre-habilitation\u002FRehabilitation Monitoring","Inclusion Criteria:\n\n1. Age 21-60\n2. Not on follow up for chronic diseases\n3. Willing to perform exercises daily x 5 days\n4. Able to handle simple technology eg. smart phone\n\nExclusion Criteria:\n\n1. Pregnant women\n2. Active joint pains and any other musculoskeletal issues\n3. Heart conditions or balance issues","60 Years",{"count":163,"type":20},20,[23],"The purpose of this research study is to validate the M5Stick Programmable watch as a prototype to monitor specific prehabilitation exercises and to monitor the frequency of exercises and the number of repetitions the subject makes in a home setting.",[167],"Rehabilitation Exercise","2025-05-06",{"date":170,"type":33},"2025-05-14",{"date":172,"type":20},"2025-06-01",{"date":174,"type":20},"2026-08-31",{"name":39,"class":40},{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":77,"enrollmentInfo":184,"targetDuration":4,"studyType":21,"phases":186,"briefSummary":187,"conditions":188,"keywords":192,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":41},"100588225","addressing-medication-non-adherence-in-patients-with-poorly-controlled-hypertension-using-urine-mass-spectrometry-100588225","NCT06938633","Addressing Medication Non-adherence in Patients With Poorly Controlled Hypertension Using Urine Mass Spectrometry","Utility of Urine Mass Spectrometry Analysis in Addressing Medication Non-adherence in Patients With Poorly Controlled Hypertension","ADURINE","Inclusion Criteria:\n\n1. Age of 21 - 80 years\n2. Systolic blood pressure of ≥140 mmHg or average systolic blood pressure ≥135 mmHg, or diastolic blood pressure ≥90 mmHg or average diastolic blood pressure ≥85 mmHg, on at least two measurements\n3. Currently taking 2 or more hypertension medications\n4. Able to provide informed consent.\n\nExclusion Criteria:\n\n* Significant kidney impairment with eGFR of less than 45mL\u002Fmin\u002F1.73m2 or on dialysis\n* Known history of chronic liver disease",{"count":185,"type":20},100,[23],"* Hypertension is the single largest contributor to cardiovascular disease and death. While adequate control of hypertension reduces risk of disease, many patients have uncontrolled hypertension. This is often due to medication non-adherence. Left undetected, patients are prescribed additional medications, and referred to multiple specialists for investigations - leading to increased healthcare costs. Hence, detecting non-adherence to antihypertensive medications is important. However, patient history, patient recall, or questionnaires, are often inaccurate. Most recently, urine measurements of antihypertensive drug levels, using mass spectrometry, has been established as the gold standard to assess medication adherence. The one-time urine test for medication adherence is ideal: It's convenient, non-invasive, economical, and can be easily performed in a clinic setting. By improving blood pressure control, this will lead to reductions in healthcare visits, avoidance of catastrophic cardiovascular events. Ultimately, this translates to significant economic savings for both patients with hypertension and the healthcare system.\n* Therefore, the investigators hypothesize that the implementation of urine adherence testing coupled with targeted counselling will improve the adherence and blood pressure control in hypertension. To do this, the investigators aim to (1) evaluate for medication adherence in 312 participants with recent stroke and hypertension; (2) evaluate for medication non-adherence in participants with uncontrolled hypertension; and (3) assess if detection of non-adherence can improve hypertension control.",[189,190,191],"Hypertension","Uncontrolled Hypertension","Non-Adherence, Medication",[193,194,195],"Urine mass spectrometry","Uncontrolled hypertension","Medication non-adherence","2025-04-14",{"date":198,"type":33},"2025-04-22",{"date":200,"type":33},"2024-02-07",{"date":202,"type":20},"2025-09-30",{"name":39,"class":40},{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":210,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":212,"enrollmentInfo":213,"targetDuration":4,"studyType":21,"phases":214,"briefSummary":215,"conditions":216,"keywords":221,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":41},"100584502","onestop-one-stop-telehealth-obesity-program-for-multidisciplinary-weight-management-and-related-comorbidities-100584502","NCT06890169","OneSTOP (One-Stop Telehealth Obesity Program) for Multidisciplinary Weight Management and Related Comorbidities","OneSTOP (One-Stop Telehealth Obesity Program): the Use of Telecare and Digital Platforms for Multidisciplinary Management of Weight Management and Related Comorbidities","OneSTOP","Inclusion Criteria:\n\n* Adults aged 21-70\n* Body mass index \\> 27.5 kg\u002Fm2\n* Waist circumference \\> 90 cm in men or 80 cm in women\n* Suboptimal control of type 2 diabetes (HbA1c \\> 6.5%) AND\u002FOR MASLD (as defined on radiological or histological evidence of hepatic steatosis in the absence of other chronic liver disease)\n\nExclusion Criteria:\n\n* Men who drink \\> 21 units\u002Fweek and women who drink \\> 14 units\u002Fweek of alcohol\n* Participants previously on weight-lowering medications (however if they are keen to participate, there will be a minimum wash-out period of 3 months before participation)\n* Illness with life expectancy of less than 6 months\n* Inability to comply with written instructions in English","70 Years",{"count":133,"type":20},[23],"The goal of this clinical trial is to learn if the use of a care model including teleconsults and the EMPOWER app can induce clinically significant weight loss and metabolic improvements in obese adults with diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD).\n\nResearchers will compare this model with the conventional standard of care of physical visit-based weight management program to see if this model is non-inferior to the standard of care for inducing weight loss, and if there is greater patient convenience with telehealth and more frequent self-monitoring, compliance with diet advice and exercise participation compared to standard of care.\n\nParticipants in the standard arm will attend 4 physical doctor and 4 physical dietician consultations over 26 weeks, where they will be provided with an individualized diet and exercise prescription to induce at least 5% weight loss.\n\nParticipants in the intervention arm will have the same number of consults over 26 weeks, of which at least 50% will be teleconsults, and will also be provided with an individualized diet and exercise prescription to induce at least 5% weight loss. In addition, they will be taught to use the EMPOWER app to upload weight, blood pressure and glucose, food and exercise records which will be reviewed at the consults. The app also delivers nudges to improve adherence to lifestyle modification.",[217,218,189,219,220],"Obesity and Type 2 Diabetes","NAFLD - Non-Alcoholic Fatty Liver Disease","Dyslipidaemia","Telemedicine",[222,223,224,225,226,227],"obesity","type 2 diabetes","masld","nafld","telecare","telemedicine","2025-03-17",{"date":230,"type":33},"2025-03-21",{"date":232,"type":20},"2025-05-01",{"date":234,"type":20},"2027-08-31",{"name":39,"class":40},{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":242,"enrollmentInfo":243,"targetDuration":4,"studyType":21,"phases":244,"briefSummary":245,"conditions":246,"keywords":248,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":258,"locationsCount":41},"100565002","a-single-arm-open-label-clinical-trial-to-evaluate-the-effect-of-smt04-in-irritable-bowel-syndrome-ibs-100565002","NCT06636513","A Single-arm, Open-label Clinical Trial to Evaluate the Effect of SMT04 in Irritable Bowel Syndrome (IBS)","Inclusion Criteria:\n\n* Male or female, aged from 21 years to 70 years old\n* Meet the criteria of the Rome-III-definition of IBS with diarrhoea or mixed subtypes, or functional diarrhoea Rome-III-definition: Abdominal pain or abdominal discomfort on minimum of three days per month during the last three months, starting at least six months ago, and a minimum of two of the following criteria:\n\n  * Improvement of symptoms after defecation\n  * Start of symptoms in association with a change in stool frequency\n  * Start of symptoms in association with a change in stool consistency Subtype of IBS-D which requires more than 25% of the participant's stools to be loose and less than 25% hard and lumpy; subtype of IBS-M which the participant's stools must be both hard and lumpy, as well as loose in consistency at least 25% of the time. Functional diarrhoea: The experience of loose or watery stools without pain occurring in at least 75% of bowel movements for at least three months over the last six months.\n* Have the latest negative colonoscopy result within five years\n* Literate and can complete questionnaire\n* Written informed consent is obtained\n\nExclusion Criteria:\n\n* Known inflammatory bowel disease, lactose intolerance or other malabsorption syndromes, celiac disease, diabetes mellitus, thyroid dysfunction, cancer, immunodeficiency, autoimmune diseases, severe hepatic or renal insufficiency, other explainable causes of abdominal pain, diarrhoea or constipation\n* Known operations involving small intestines and large intestines; or history of appendectomy, hysterectomy, and cholecystectomy in last 6 months.\n* Known severe mental illnesses; unstable type or dose of psychiatric drugs within the last 3 months that will affect their judgement of study participation.\n* Evidence of active infection at the time of inclusion\n* History of use of prebiotics, probiotics, antibiotic therapy or anti-inflammatory drugs within the last 2 weeks\n* Known current pregnancy or breast-feeding female","55 Years",{"count":19,"type":20},[23],"Probiotic supplements improve IBS symptoms through manipulation of the gut microbiota. Metabolites derived from microbiota metabolism and host-microbiota co-metabolism have an impact on host intracellular signalling pathways. Although probiotic supplements improve IBS symptoms, the precise composition of probiotics that can achieve optimal response remains unclear. SMT04 (M3XTRA, GenieBiome Limited, Hong Kong, China) is a novel product that is commercially available as a dietary supplement in Singapore. It consists of a patented probiotics blend of 5 probiotics (3 Bifidobacteria and 2 Streptococci with 12.5 billion CFU in 1 sachet). Probiotics preparation that included varying composition of Bifidobacteria and Streptococci strains had previously demonstrated efficacy in achieving symptom improvement in IBS patients. Streptococcus thermophilus, a component of the blended probiotics, significantly improved intestinal functional barrier in healthy subjects. Thus there is potential for SMT04, a dietary supplement, to be a treatment option for IBS patients. This is a multi-centered trial, all data and samples from the study sites will be pooled together for analysis.",[247],"Irritable Bowel Syndrome",[249,250,251],"probiotic","IBS","microbiota","2025-02-11",{"date":254,"type":33},"2025-02-12",{"date":256,"type":33},"2024-03-20",{"date":94,"type":20},{"name":39,"class":40},{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":266,"minAge":16,"maxAge":4,"enrollmentInfo":267,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":269,"conditions":270,"keywords":274,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":41},"100573982","breast-cancer-rehabilitation-needs-and-service-uptake-100573982","NCT06753357","Breast Cancer Rehabilitation Needs and Service Uptake","Prevalence of Cancer Rehabilitation Needs and Drivers of Rehabilitation Service Uptake in Breast Cancer Survivors","Inclusion Criteria:\n\n1. Female patients\n2. Age 21yrs old and above\n3. Histological diagnosis of breast cancer at any stage (or clinical consensus at a Tumour Board meeting, for example if the condition is metastatic and biopsy is not indicated for any reason)\n4. Started treatment (surgical, medical, radiotherapeutic, or otherwise) with curative or palliative intent\n5. Speak English, Mandarin, or Malay, or Tamil, and are able to understand a verbally-translated version of the questionnaire\n6. Able to provide informed consent\n\nExclusion Criteria:\n\n1. Unable to answer the questionnaire for any reasons such as cognitive impairment or sensory dysfunction\n2. Declined participation","FEMALE",{"count":268,"type":20},376,"The investigators are attempting to verify the prevalence of cancer rehabilitation needs at our institution in breast cancer patients. The investigators also want to assess 1) self-perceived needs for cancer rehabilitation services, 2) awareness, willingness, and patient health beliefs as determinants for cancer rehabilitation-seeking behaviour, and 3) the modifiable patient factors driving the mismatch between needs and uptake in our population.\n\nPatients attending outpatient clinics in our hospital will be approached to answer a questionnaire designed to find out this information. The investigators hope that the results will ultimately inform the design of better triage and referral systems that match patients to services based on their rehabilitation needs.\n\nThe investigators believe that local survivors of breast cancer have unmet rehabilitation needs and that it is possible to evaluate their readiness to seek access to rehabilitation services as well as identify mismatches between provided and desired services through the administration of a cancer rehabilitation questionnaire (CRQ).",[271,272,273],"Breast Cancer","Cancer Survivorship","Health Attitude",[275,276,277,278,279,280,281],"Breast cancer","Cancer rehabilitation","Rehabilitation needs","Rehabilitation service uptake","Cancer survivorship","Health Belief Model","Technological enablers","2024-12-22",{"date":284,"type":33},"2024-12-31",{"date":286,"type":20},"2025-01",{"date":288,"type":20},"2025-12",{"name":39,"class":40},{"id":291,"slug":292,"hasResults":11,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":4,"eligibilityCriteria":296,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":297,"targetDuration":299,"studyType":80,"phases":4,"briefSummary":300,"conditions":301,"keywords":303,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":41},"100556641","body-composition-frailty-and-function-in-rehabilitation-100556641","NCT06527742","Body Composition, Frailty, and Function in Rehabilitation","Correlations of Body Composition Measures with Functional Outcomes and the Clinical Frailty Scale in Inpatient Rehabilitation: a Prospective Cohort Study","Inclusion Criteria:\n\n1. Transferred under the Rehabilitation Medicine service for post-acute rehabilitation\n2. Rehabilitation diagnosis of:\n\n   1. Stroke with motor weakness (modified Rankin scale 1-5), or\n   2. Deconditioning (from sepsis, post-ICU admission, heart failure, falls, musculoskeletal conditions with or without pain, or other conditions), or\n   3. Pulmonary rehabilitation (with or with long-term oxygen therapy), or\n   4. Lower limb amputees (transtibial or transfemoral)\n3. Medically stable\n4. Able to understand English consent form or suitably-translated document, or have a family member\u002Flegally-authorised representative who is able to do so and willing to provide consent\n\nExclusion Criteria:\n\n1. Pacemaker or implantable defibrillator in-situ\n2. Medical devices or surgical implants that will interfere with BIA measurement per the manufacturer's guidelines\n3. Abnormal fluid status (overloaded or depleted) at the point of screening\n4. Cognitive or physical inability to tolerate sitting\u002Flying still for 2mins (for BIA measurement)",{"count":298,"type":20},345,"2 Months","The investigators are investigating if body composition measures - in particular muscle mass, body fat, and something called the phase angle - are able to reliably predict functional outcomes for patients who are in an acute hospital for inpatient rehabilitation. The investigators also want to see if age and frailty affect these relationships.\n\nPatients undergoing inpatient rehabilitation in our hospital will be monitored through a variety of frailty-specific tools, including strength and speed. The investigators will use a device called a body composition monitor (BCM) to record their body composition measurements. These will then be compared against their usual rehabilitation outcomes.\n\nThe investigators believe that there is a correlation between these measures and a patient's functional outcomes.",[56,113,302],"Debility Due to Disease",[113,56,57,304,305,306,307,308,309],"Deconditioning","Body fat","Skeletal muscle mass","Phase angle","Bioimpedance analysis","Body composition measurement","2024-12-17",{"date":312,"type":33},"2024-12-19",{"date":314,"type":33},"2024-12-09",{"date":316,"type":20},"2025-09",{"name":39,"class":40},""]